Be­hind the deal spree, Cel­gene con­tin­ues to cau­tious­ly ex­plore neu­ro­sciences

Two years ago dur­ing a lunch with a group of re­porters at the JP­Mor­gan con­fab, then Cel­gene CEO (now ex­ec­u­tive chair­man) Bob Hug­in got my at­ten­tion with a com­ment on the im­por­tance of neu­ro­sciences in the pipeline.

Any com­pa­ny that ex­pects to have a ma­jor po­si­tion in the in­dus­try a decade from now will al­most have to play a big role in de­vel­op­ing ther­a­pies for neu­rode­gen­er­a­tion, he told us, mak­ing it clear that he wasn’t talk­ing about some sud­den splurge on neu­rode­gen­er­a­tion deals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER